Welcome to our dedicated page for Vicarious Surgical news (Ticker: RBOT), a resource for investors and traders seeking the latest updates and insights on Vicarious Surgical stock.
Vicarious Surgical Inc (RBOT) combines advanced robotics with virtual reality to transform minimally invasive surgery. This news hub provides investors and healthcare professionals with essential updates about the company's technological advancements and market position.
Access real-time information about surgical robotics innovations, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, product development announcements, and clinical trial updates directly impacting the future of abdominal surgery techniques.
Key focus areas include 3D visualization systems, single-port surgical interfaces, and integration with existing hospital workflows. Stay informed about developments in robotic-assisted procedures that enhance surgical precision while reducing patient recovery times.
Bookmark this page for verified updates about RBOT's progress in medical robotics. Regularly updated content ensures you maintain current awareness of technological breakthroughs and industry partnerships shaping modern surgical practices.
Vicarious Surgical, Inc. (NYSE:RBOT) has successfully qualified its cleanroom for manufacturing the Vicarious System, enhancing its capabilities for precision assembly. This qualification ensures adherence to stringent efficiency and quality standards, marking a significant step towards market readiness. The Vicarious System aims to improve surgical outcomes by facilitating procedures through a single port, promoting faster patient recovery. CEO Adam Sachs emphasized the importance of a quality-controlled manufacturing process in achieving better healthcare outcomes.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced the appointment of John Mazzola as vice president of operations. With over 30 years in the medical device industry, Mazzola aims to enhance the company’s manufacturing strategies for its next-generation surgical robotics. Prior to joining Vicarious, he held senior roles at Becton Dickinson, overseeing 10 manufacturing sites. CEO Adam Sachs expressed confidence in Mazzola's expertise to drive operational growth. Mazzola's active involvement in industry associations adds to his credentials.
Vicarious Surgical (NYSE: RBOT, RBOT WS) reported preliminary unaudited financial results for Q4 and the full year 2021. The company experienced a significant increase in operating expenses, totaling $18.2 million in Q4, up 380% year-over-year. Adjusted net loss for Q4 was $18.2 million, or $0.15 per share, compared to a loss of $3.8 million, or $0.04 per share in the prior year. Full year operating expenses reached $38.6 million, reflecting a 197% increase. Cash and cash equivalents stood at $173.5 million as of December 31, 2021.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in two upcoming virtual investor conferences. The Cowen 42nd Annual Healthcare Conference will feature a presentation on
Vicarious Surgical Inc. (NYSE: RBOT) will release its fourth quarter 2021 financial results on March 3, 2022, after market close. A conference call, starting at 4:30 p.m. ET, will follow to discuss the results. Investors can participate by calling 1 (646) 904 5544 domestically or +1 (929) 526 1599 internationally. Vicarious Surgical, founded in 2014, focuses on enhancing surgical efficiency and reducing healthcare costs using proprietary robotic technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will engage in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 4:00 p.m. Eastern Time. The company focuses on enhancing surgical procedures through next-generation robotic technology, which has been recognized by the FDA with a Breakthrough Device Designation. Founded in 2014, Vicarious Surgical aims to improve patient outcomes while reducing healthcare costs. The event is accessible via BTIG representatives.
Vicarious Surgical has been recognized with three awards in Built In’s 2022 Best Places To Work Awards, including Best Places to Work, Best Midsize Companies to Work for, and Best Paying Companies in Boston. The awards program evaluates company data on compensation and benefits, adapting to the changing needs of tech professionals. CEO Adam Sachs emphasized the company's commitment to employee success as it grows. Founded in 2014, Vicarious Surgical focuses on innovative surgical robotics and has received Breakthrough Device Designation from the FDA for its technology.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its participation in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation will be accessible from November 22, 2021, at 10:00 a.m. Eastern Time on their website. Founded in 2014, Vicarious Surgical is innovating surgical procedures using advanced robotics and virtual reality technology, aiming to enhance efficiency and patient outcomes. Their technology is recognized with Breakthrough Device Designation by the FDA, marking a significant milestone in surgical robotics.
Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) announced its third quarter 2021 financial results, marking its entry into public markets. The company posted an operating expense of $8.6 million, a 156.2% increase from the previous year. R&D expenses rose to $5.2 million while general and administrative costs increased to $2.5 million. The net loss reached $65.5 million, showing a significant increase from $3.3 million in Q3 2020, resulting in a net loss per share of $0.71. However, cash reserves stood strong at $185 million as of September 30, 2021.
FAQ
What is the current stock price of Vicarious Surgical (RBOT)?
What is the market cap of Vicarious Surgical (RBOT)?
